Provided by Tiger Fintech (Singapore) Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.72
-0.0100-0.58%
Post-market: 1.70-0.0200-1.16%19:58 EDT
Volume:563.44K
Turnover:977.33K
Market Cap:91.96M
PE:-2.58
High:1.79
Open:1.72
Low:1.67
Close:1.73
Loading ...

BRIEF-Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting

Reuters
·
16 Jun

Milestone Pharmaceuticals Submits Response to the FDA’s Crl for Cardamyst (Etripamil) Nasal Spray for Psvt Following Type a Meeting

THOMSON REUTERS
·
16 Jun

Milestone Pharmaceuticals Inc: Believe Type a Meeting With FDA Provided Guidance to Submit Response to Crl Directly After Meeting

THOMSON REUTERS
·
16 Jun

Milestone Pharmaceuticals Inc - FDA to Determine Acceptance of Response and Pdufa Date Within 30 Days

THOMSON REUTERS
·
16 Jun

Milestone Pharmaceuticals Inc - Review Time Expected to Be Within 2 or 6 Months From Resubmission

THOMSON REUTERS
·
16 Jun

Milestone Pharmaceuticals Inc. Conducted Annual Shareholders Meeting

Reuters
·
13 Jun

Milestone Pharmaceuticals Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
05 Jun

Milestone Pharmaceuticals’ Path to Approval: Addressing CMC Issues for Cardamyst’s Market Potential

TIPRANKS
·
05 Jun

Milestone Pharmaceuticals Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $5

THOMSON REUTERS
·
05 Jun

TD Cowen Sticks to Their Hold Rating for Milestone Pharmaceuticals (MIST)

TIPRANKS
·
19 May

Milestone Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

BRIEF-Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results

Reuters
·
14 May

Milestone Pharmaceuticals Q1 EPS $(0.31) Misses $(0.18) Estimate

Benzinga
·
14 May

Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update

THOMSON REUTERS
·
14 May

Milestone Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
09 May

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Investing.com
·
02 Apr

Milestone Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
02 Apr

Milestone Pharmaceuticals Inc : H.c. Wainwright Cuts Target Price to $10 From $25

THOMSON REUTERS
·
01 Apr

BUZZ-Milestone Pharma falls after TD Cowen downgrades to "hold", removes PT

Reuters
·
01 Apr

HC Wainwright Adjusts Price Target on Milestone Pharmaceuticals to $10 From $25, Maintains Buy Rating

MT Newswires Live
·
01 Apr